钠—葡萄糖协同转运蛋白2抑制剂在糖尿病心肌病中作用机制的研究进展

Research progress on role and mechanism of Sodium-Glucose Cotransporter-2 inhibitor in diabetic cardiomyopathy

糖尿病心肌病(Diabetic cardiomyopathy,DCM)是排除高血压,冠心病,先天性心脏病等其他心血管疾病后的特异性心肌病,临床上其发病率持续增高,但是DCM的早期筛查手段和治疗方法仍然有限。因此当务之急是寻找一种敏感可靠的治疗药物,降低DCM的发病率。有大量的临床试验证实,钠—葡萄糖协同转运蛋白2抑制剂(Sodium-Glucose Cotransporter-2 Inhibitor,SGLT2i)治疗有利于糖尿病心肌病的代谢、微循环、线粒体功能、纤维化、氧化应激、内质网应激、程序性细胞死亡、自噬和肠道菌群等。本文就SGLT2i治疗DCM作用机制的最新研究进展进行综述,以期为临床早期治疗DCM提供参考。

Diabetic cardiomyopathy(DCM)is a specific cardiomyopathy that excludes hypertension,coronary heart disease,congenital heart disease and other cardiovascular diseases.The clinical incidence of DCM continues to increase,but the early screening methods and treatment methods for DCM are still limited.Therefore,the urgent task at present is to find a sensitive and reliable treatment drug to reduce the incidence of DCM.There are numerous clinical trials that confirm,Sodium-Glucose Cotransporter-2 Inhibitor(SGLT2i)treatment is beneficial to metabolism,microcirculation,mitochondrial function,fibrosis,oxidative stress,endoplasmic reticulum stress,programmed cell death,autophagy and intestinal flora in diabetic cardiomyopathy.This article reviews the latest research progress on the mechanism of action of SGLT2i in the treatment of DCM,in order to provide reference for the early clinical treatment of DCM.